Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
News|Videos|April 16, 2025 (Updated: April 18, 2025)
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Author(s)Benjamin Weinberg, MD
Dr. Benjamin Weinberg presents findings from a ctDNA-based analysis of the CALGB/SWOG 80702 trial, showing that circulating tumor DNA status may help identify patients with stage III colon cancer who could benefit from celecoxib added to standard adjuvant chemotherapy, offering a potential biomarker-driven approach to personalized treatment.
Advertisement
Advertisement
Related to this article
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
5